Table 1.
CRP ≤ 2 mg/L (N = 21) | CRP > 2 mg/L (N = 19) | p value | ||
---|---|---|---|---|
Age | Mean (SD) | 34.0 (10.6) | 38.5 (11.4) | 0.206a |
Sex | Male, N (%) | 9 (42.9) | 3 (15.8) | 0.089b |
Race | White, N (%) | 13 (61.9) | 11 (57.9) | 0.967c |
Black, N (%) | 7 (33.3) | 7 (36.8) | ||
Asian, N (%) | 1 (4.8) | 1 (5.3) | ||
BMI | Mean (SD) | 26.0 (4.3) | 31.2 (5.9) | 0.003a |
CRP (mg/L) | Median (IQR) | 1.0 (1.1) | 3.63 (1.4) | <0.001d |
Inflammatory Scoref | Mean (SD) | −1.2 (2.5) | 1.2 (3.1) | 0.011a |
HAM-D | Mean (SD) | 21.5 (3.2) | 22.0 (3.9) | 0.677a |
IDS-SR | Mean (SD) | 34.5 (9.4) | 39.2 (5.7) | 0.069a |
EEfRT (proportion hard choices per % probability win)g | ||||
12%, Post-Placebo | Mean (SD) | 0.14 (0.22) | 0.08 (0.12) | 0.309e |
12%, Post-L-DOPA | Mean (SD) | 0.14 (0.22) | 0.09 (0.16) | 0.487e |
50%, Post-Placebo | Mean (SD) | 0.33 (0.24) | 0.23 (0.22) | 0.202e |
50%, Post-L-DOPA | Mean (SD) | 0.34 (0.25) | 0.23 (0.26) | 0.218e |
88%, Post-Placebo | Mean (SD) | 0.58 (0.18) | 0.51 (0.33) | 0.428e |
88%, Post-L-DOPA | Mean (SD) | 0.52 (0.21) | 0.53 (0.32) | 0.845e |
Anhedonia (momentary SHAPS score) | ||||
SHAPS Pre-Placebo | Mean (SD) | 4.0 (3.5) | 5.4 (4.3) | 0.259e |
SHAPS Post-Placebo | Mean (SD) | 3.1 (3.3) | 5.3 (4.4) | 0.091e |
SHAPS Pre-L-DOPA | Mean (SD) | 4.1 (3.1) | 4.9 (4.2) | 0.466e |
SHAPS Post-L-DOPA | Mean (SD) | 3.6 (3.4) | 3.9 (4.4) | 0.762e |
Plasma L-DOPA (nM) | Median (IQR) | 5650 (6085) | 7370 (6130) | 0.215d |
Plasma DA (nM) | Median (IQR) | 9.72 (5.84) | 9.08 (6.86) | 0.893d |
CRP C-reactive protein, BMI body mass index, DA dopamine, EEfRT Effort Expenditure for Rewards Task, HAM-D Hamilton Depression Rating Scale, L-DOPA levodopa, SHAPS Snaith-Hamilton Pleasure Scale, SD standard deviation, IQR interquartile range.
Bold text indicates p < 0.05.
aT-test.
bFisher’s exact test.
cPearson’s Chi-squared test.
dKruskal–Wallis rank sum test.
eMultivariate linear ANOVA.
fn = 20 for CRP ≤ 2 mg/L group.
gn = 17 for CRP > 2 mg/L group.